文献速递膀胱癌与上尿路尿路上皮癌

癌胚糖胺聚糖修饰为顺铂耐药膀胱癌提供治疗途径

An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
PubMed 文献 · Eur Urol · 2017-04-10

研究探讨癌胚硫酸软骨素(ofCS)糖胺聚糖链在顺铂耐药肌层浸润性膀胱癌(MIBC)中的临床意义及作为二线治疗靶点的价值。在两组独立的新辅助化疗(NAC)前后匹配MIBC患者队列中,残余肿瘤ofCS显著过表达(p<0.02);体外实验中VDC886在低纳摩尔IC50范围清除所有受试MIBC细胞系;体内实验中VDC886有效延缓耐药原位膀胱癌异种移植瘤生长并延长生存(p=0.005)。作者认为靶向ofCS为顺铂耐药MIBC提供了有前景的二线治疗策略。

要点

  • 两组独立NAC前后匹配MIBC队列中,残余肿瘤ofCS显著过表达(p<0.02)。
  • 体外所有受试MIBC细胞系表达ofCS,VDC886在低纳摩尔IC50范围清除这些细胞。
  • 体内VDC886有效延缓化疗耐药原位膀胱癌异种移植瘤生长并延长生存(p=0.005)。

核心结论

  • 靶向ofCS为顺铂耐药MIBC提供了有前景的二线治疗策略。

研究设计与样本

  • 使用源自恶性疟原虫(Plasmodium falciparum)的ofCS结合重组VAR2CSA蛋白(rVAR2)作为原位、体外和体内ofCS靶向试剂,研究顺铂耐药MIBC。
  • 在两组独立的NAC治疗前后匹配MIBC患者队列中分析ofCS表达谱。
  • 在顺铂耐药MIBC异种移植模型中评估携带细胞毒性hemiasterlin化合物的rVAR2蛋白(rVAR2药物偶联物[VDC]886)作为新型治疗策略。

主要发现

  • 原位实验中,两组独立患者队列NAC后残余肿瘤ofCS显著过表达(p<0.02)。
  • 原发肿瘤和细胞系的全局基因表达谱和生化分析显示syndecan-1和硫酸软骨素蛋白聚糖4是MIBC中ofCS修饰的蛋白聚糖。
  • 体外实验中,所有受试MIBC细胞系均表达ofCS,VDC886在低纳摩尔IC50浓度范围清除这些细胞。
  • 体内实验中,VDC886有效延缓化疗耐药原位膀胱癌异种移植瘤生长并延长生存(p=0.005)。

局限性

  • 仅使用顺铂生成化疗耐药异种移植瘤是本动物模型设计的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although cisplatin-based neoadjuvant chemotherapy (NAC) improves survival of unselected patients with muscle-invasive bladder cancer (MIBC), only a minority responds to therapy and chemoresistance remains a major challenge in this disease setting. OBJECTIVE: To investigate the clinical significance of oncofetal chondroitin sulfate (ofCS) glycosaminoglycan chains in cisplatin-resistant MIBC and to evaluate these as targets for second-line therapy. DESIGN, SETTING, AND PARTICIPANTS: An ofCS-binding recombinant VAR2CSA protein derived from the malaria parasite Plasmodium falciparum (rVAR2) was used as an in situ, in vitro, and in vivo ofCS-targeting reagent in cisplatin-resistant MIBC. The ofCS expression landscape was analyzed in two independent cohorts of matched pre- and post-NAC-treated MIBC patients. INTERVENTION: An rVAR2 protein armed with cytotoxic hemiasterlin compounds (rVAR2 drug conjugate [VDC] 886) was evaluated as a novel therapeutic strategy in a xenograft model of cisplatin-resistant MIBC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Antineoplastic effects of targeting ofCS. RESULTS AND LIMITATIONS: In situ, ofCS was significantly overexpressed in residual tumors after NAC in two independent patient cohorts (p<0.02). Global gene-expression profiling and biochemical analysis of primary tumors and cell lines revealed syndican-1 and chondroitin sulfate proteoglycan 4 as ofCS-modified proteoglycans in MIBC. In vitro, ofCS was expressed on all MIBC cell lines tested, and VDC886 eliminated these cells in the low-nanomolar IC50 concentration range. In vivo, VDC886 effectively retarded growth of chemoresistant orthotopic bladder cancer xenografts and prolonged survival (p=0.005). The use of cisplatin only for the generation of chemoresistant xenografts are limitations of our animal model design. CONCLUSIONS: Targeting ofCS provides a promising second-line treatment strategy in cisplatin-resistant MIBC. PATIENT SUMMARY: Cisplatin-resistant bladder cancer overexpresses particular sugar chains compared with chemotherapy-naïve bladder cancer. Using a recombinant protein from the malaria parasite Plasmodium falciparum, we can target these sugar chains, and our results showed a significant antitumor effect in cisplatin-resistant bladder cancer. This novel treatment paradigm provides therapeutic access to bladder cancers not responding to cisplatin.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Seiler R, Oo HZ, Tortora D, et al. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer. Eur Urol. 2017. PMID: 28408175. doi:10.1016/j.eururo.2017.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。